pitrakinra
Pitrakinra is a 15-kDa human recombinant protein of wild-type human interleukin-4 (IL-4). It is an IL-4 and IL-13 antagonist that has been studied in a phase IIb clinical trial for the treatment of asthma. Two point mutations on pitrakinra confer its ability to block signaling of IL-4 and interleukin-13 (IL-13) by preventing assembly of IL-4 receptor alpha (IL-4Rα) with either IL-2Rγ or IL-13Rα. Upregulation of Th2 cytokines, including IL-4 and IL-13, is thought to be critical for the allergic inflammation associated with atopic diseases such as asthma and eczema. The targets of pitrakinra action are inflammatory cells and structural cells that express IL-4Rα. The drug has been applied both as a subcutaneous injection and as an inhalation, but the latter formulation proved to be more effective. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2006 (NCT00676884)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-4ANTAGONIST
IL4 antagonist
- Interleukin-13ANTAGONIST
IL13 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPitrakinra ↗
- ChEMBLCHEMBL2109159 ↗
Also known as
- pitrakinra
- pitrakinra
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00801853 | Phase 2 | Mar 1, 2009 | Aerovance, Inc., University of Pittsburgh |
| NCT00676884 | Phase 2 | Feb 1, 2006 | Aerovance, Inc., University of London |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aerovance, Inc. | For profit | 2 | 2 | 1 | 2006 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2009 |